Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aimei Health Technology (AFJK) Shares Outstanding (Weighted Average) (2023 - 2025)

Aimei Health Technology (AFJK) has 3 years of Shares Outstanding (Weighted Average) data on record, last reported at $4.4 million in Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 36.54% to $4.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.4 million, a 36.54% decrease, with the full-year FY2024 number at $2.1 million, up 38.21% from a year prior.
  • Shares Outstanding (Weighted Average) reached $4.4 million in Q3 2025 per AFJK's latest filing, up from $4.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for AFJK hit a ceiling of $6.9 million in Q1 2024 and a floor of $1.5 million in Q4 2023.
  • A 3-year average of $4.7 million and a median of $4.8 million in 2025 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 38.21% in 2024, then crashed 42.09% in 2025.
  • Tracing AFJK's Shares Outstanding (Weighted Average) over 3 years: stood at $1.5 million in 2023, then soared by 38.21% to $2.1 million in 2024, then skyrocketed by 105.96% to $4.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AFJK at $4.4 million in Q3 2025, $4.0 million in Q2 2025, and $5.2 million in Q1 2025.